0000-0002-0261-460X About
The primary research interests of Dr. Ghosh’s laboratory are to screen and develop medical countermeasures for acute radiation syndrome (ARS) in murine model following guidelines established by the US FDA Animal Rule. Her focus on the development of drugs and treatment approaches are designed to prevent, mitigate, or reverse health damage resulting from exposure to ionizing radiation. The potential for exposure to harmful doses of ionizing radiation exists in a wide variety of scenarios including accidents in nuclear facilities as well as nuclear detonation. Her effort is to identify radiation countermeasures / drugs that belong to various classes such as antioxidants/immunostimulants, growth factors, or cellular products, that can reconstitute the immune system and/or overcome reactive oxygen species-induced biological changes in in vivo animal models. She uses a mouse model to screen various countermeasures exposed to γ-irradiation in AFRRI’s unique pool-type Cobalt 60 facility. Over the years, she has served as Principal Investigator in the Radiation Countermeasure Program with financial support from DTRA, DMRDP, JPC-7, NIAID-AFRRI Inter Agency Agreement (IAA), and intramural grants. She also serves as the Chair of the AFRRI Intramural Screening Program.
Her laboratory has extensive experience in studying the hematopoietic and gastrointestinal ARS following total-body and partial-body irradiation using murine model, and the effects of various radiation countermeasures on injury and recovery. To date, she has evaluated over 30 different compounds/drugs in the mouse model through material transfer agreement. Out of these candidates, 4 candidates emerged as promising countermeasures both as a prophylactic radiation countermeasure as well as a mitigator in the murine model. Her laboratory has identified a list of time-informed critical markers and mechanisms of significant translational potential in the context of a radiation exposure event using serum miRNAs and metabolites. She collaborates with academic institutions, DoD laboratories, and corporate collaborators in US as well as overseas. In summary, She has accomplished various research projects in AFRRI (Extramural and Intramural) which involves developing countermeasures in mouse models, developing partial body irradiated (gut and lung specific) mouse models in SARRP, studying radiation responses in biofluids and tissues from irradiated mice from total body as well as partial body irradiated (gut and lung specific), differential expression of microRNA/metabolites in mouse tissues after radiation.
Employment
-
Armed Forces Radiobiology Research Institute Senior Principal Investigator2005 - Present
Education
-
Armed Forces Radiobiology Research Institute Ph.D.1990 - Present
Projects & Funding
Projects & funding information is unavailable.
Publications (42)
- LA-GM-CSF, a Long-Acting Cytokine Mitigates and Prevents H-ARS Mediated Lethality in Mice Exposed to Total Body Gamma Radiation Save
- Expanding the Treatment Window for the FDA-Approved Radiation Countermeasure Nplate Save
- JNJ-26366821 Attenuates Radiation-Induced Pro-Inflammatory Cytokines and miRNAs and Triggers TR/RXR Signaling Pathway Save
- FSL-1 Pre-Administration Protects Radiation-Induced Hematopoietic Organs Through the Modulation of the TLR Signaling Pathway Save
- Delayed Impact of Ionizing Radiation Depends on Sex: Integrative Metagenomics and Metabolomics Analysis of Rodent Colon Content Save
- Ionizing Radiation Dose Differentially Affects the Host–Microbe Relationship over Time Save
- Time- and sex-dependent delayed effects of acute radiation exposure manifest via miRNA dysregulation Save
- CDX-301 prevents radiation-induced dysregulation of miRNA expression and biogenesis Save
- Dysregulated Cardiac IGF-1 Signaling and Antioxidant Response Are Associated with Radiation Sensitivity Save
- microRNA and Metabolite Signatures Linked to Early Consequences of Lethal Radiation Save